Results 291 to 300 of about 885,175 (334)

Comment on: “Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis”

Muhammed Shabil, Ganesh Bushi, Nishant Rai, Hashem Abu Serhan   +3 more
openalex   +1 more source

Case Report: Recurrent supraglottitis in a patient with metastatic melanoma treated with ipilimumab and nivolumab. [PDF]

Front Oncol
Palmeri M, Weiss SA, Purnell P.
europepmc   +1 more source

High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors. [PDF]

J Transl Med
Guida M, Apollonio B, Romano L, Spagnolo F, Quaglino P, Depenni R, Pinto R, Squicciarini T, Fucci L, Di Tullio P, Scaini MC, Maccallini MT, Indini A, Troiani T, Natalicchio I, Brugnara S, Lombardo M, Pellegrini C, Queirolo P, Perrone F, Minisini A, Tucci M, Conca R, Costabile S, Macrì M, Tanda E, Croce E, Senetta R, Fava P, Pugliese G, Pellegrini S, Melucci E, Vecchio MD, Caraglia F, Girlando S, De Summa S, Strippoli S, Italian Melanoma Intergroup (IMI).   +37 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Metastatic melanoma

Current Treatment Options in Oncology, 2001
The overall survival for patients with metastatic melanoma ranges from 4.7 to 11 months, with a median survival of 8.5 months. Standard treatment for patients with metastatic melanoma has not been defined. The range of treatment options includes close observation, surgical resection of isolated metastases, therapy with dacarbazine, combination ...
W, Sun, L M, Schuchter
openaire   +2 more sources